Member Info for rivaldo

Excellent stuff: - good H1 results and very confident outlook for a profitable H2 - acquisition at 23p and oversubscribed placing at 22p - Kinesis Pharma already makes historic €0.6m EBITDA so is nicely earnings enhancing No reason why the share price shouldn't continue to advance from here imo. Brief analyst comment amongst other coverage: http://www.proactiveinvestors.co.uk/companies/news/110995/venn-life-sciences-to-offer-one-stop-shop-service-with-kinesis-pharma-deal-110995.html "William Lynne at broker Hybridan said Venn was a good match with Kinesis. He added that half-yearly results were well on track to meet market expectations, with €9m in new contract wins. "Combined with the accretive contribution from Kinesis, the future looks very promising," he said."

Adjusted EPS of 16.19p, plus an earnings-enhancing acquisition, and post year end trading is in line with expectations. And most intriguingly, a strategic review, likely to sell the low margin aftermarket businesses and leave shareholders with the excellent data erasure and other high-tech divisions (Blancco etc), which have been strengthened with today's acquisition. All of that lot should get the share price going nicely.

As Liberum (EDIT - not Singer!) state this morning: "Strong cash flow with net cash from operating activities of $12.1m (+111%) bolstered an already healthy balance sheet - net cash and short term investments were $43.2m at the period end". The cash pile is forecast to increase to over $46m at the year end - though of course we can expect more earnings-enhancing acquisitions from that cash pile.

As Singer state this morning: "Strong cash flow with net cash from operating activities of $12.1m (+111%) bolstered an already healthy balance sheet - net cash and short term investments were $43.2m at the period end". The cash pile is forecast to increase to over $46m at the year end - though of course we can expect more earnings-enhancing acquisitions from that cash pile.

Liberum retain their Buy and 103p target, and say "The shares are unquestionably cheap on any metric." They conclude: "The shares are currently undervalued on all metrics. Arguably, as an operator agnostic company in a high growth market, the rating warrants a premium to quoted peers. However, even assuming that the shares re-rate towards sector average multiples (EV/EBITDA, EV/Sales, P/E etc.) then an average of the implied value and our DCF analysis, generates a target share price of 100p+" Nice to see them agree with me that XLM warrant a premium to their peers :o))

Absolutely outstanding. The $11.4m PAT and 2.595c divi suggest full year forecasts will be thrashed. No wonder they're "extremely confident" they'll meet expectations! And they're back up to a $43m cash pile despite the acquisitions. XLM really should be trading on a premium rating, not a discounted one. At say 100p+ for starters.

An exciting day yesterday by VLE's standards :o)) 15 buy trades, and no sells, totalling 22,610 shares in 1k and 2k lots - yet the share price is unchanged. Great to finally have some liquidity, with a seller meeting demand for shares pre-interims, which should be next week as usual.. I'm starting to get intrigued (and it's about time!) by Sira's prospects following the tie-up this Feb'15 with the American company MotionDSP via their product Ikena Forensic 5.0. For example, in April MotionDSP announced this use of IK5.0 by the International Justice Mission: Https://www.motiondsp.com/news/press-release/international-justice-mission-deploys-motiondsp-bolster-investigation-efforts/ And this from April'15 (p.3) shows Sira being awarded a £24k contract by the Met Police for support and maintenance for Siraview software, so they're evidently still using it: hxxp://www.met.police.uk/foi/pdfs/lists_and_registers/corporate/contracts_over_%C2%A32500_q4_january_march_2015.pdf

Late RNS yesterday shows Hargreave Hale going above 15% with 11.04m shares - they've bought 700,000 shares since their last holdings RNS: Http://www.investegate.co.uk/harvey-nash-group--hvn-/rns/holding-s--in-company/201509171707574407Z/ In particular, Marlborough Fund Managers within that holding have increased from 9.64m shares to 10.385m shares. Tempted to add myself before the interims, which will be on 30th September (2 weeks' time), given the positive/trading in line AGM statement.

Http://www.arabianaerospace.aero/gama-aviation-adds-first-learjet-75-to-its-fleet.html "Gama Aviation adds first Learjet 75 to its fleet Posted 16 September 2015 · Gama Aviation has taken on the management of its first Learjet 75, having overseen the delivery of the new aircraft from Bombardier. The aircraft has been added to the Gama Aviation fleet on behalf of one of the company’s long-standing US customers and is expected to be based in Central America. The new model joins the Learjet 45, 45XR and 60 aircraft, as well as aircraft from Bombardier’s Challenger and Global series, which Gama Aviation already operate for their clients across the US, Europe and China. In total, Gama Aviation’s worldwide fleet now includes more than 30 different aircraft types. KC Ihlefeld, VP aircraft management of Gama Aviation said: “As a business we pride ourselves on being able to offer our customers expert support across a wide range of aircraft types and we’re delighted to add the Learjet 75 to our stable. We have hands on experience with aircraft from all the major OEMs and this enables us to provide clients with a consistent level of service, no matter what the aircraft type or their mission requirements. “It is a resounding endorsement of the relationship we aim to build with clients that when customers want to change or add additional aircraft they seek our help in arranging the transition and delivery and continue to trust us with their management. It is these long standing relationships that are the best indication of the service we provide.”"

....that's 2 in 3 days..... http://www.investegate.co.uk/constellation-health/rns/acquisition/201509180700054488Z/ Paying a max $14m (25% in performance-related shares) for $2.2m EBITDA sounds like a bargain to me. And CHT say it will be immediately earnings-enhancing. Plus there'll be considerable savings from cost synergies etc. Forecasts will have to be raised again.

Thanks for that shan, good article from Edmond Jackson. The link is here as it's a much longer article than in your post, with this conclusion: http://www.iii.co.uk/articles/266467/stockwatch%3A-buy-five-year-plan "All considered, it looks fair to regard risk as being on the upside, targeting 175p to 200p a share over the next two years as earnings and their rating improve. While this kind of business is in the front-line of any recession, Creston's financial strength would enable it to make attractively-priced acquisitions in a downturn. Customers also tend to be loyal to their marketing agencies even though budgets can vary. So despite the chart high, there are good reasons to consider the stock as a tuck-away."

today for this off-the-radar stock: Http://www.investegate.co.uk/constellation-health--cht-/rns/acquisition/201509160700211712Z/ $18m acquisition, of which $11.5m in cash and the balance in shares dependent on meeting financial targets - so nicely played by CHT. Not only earnings-enhancing, but also further synergies to come - and it already makes $1.9m historic EBITDA. Finncap retain their 280p target and conclude as follows: "Constellation has progressed its strategy of building a major provider of US medical billings services with the acquisition of NorthStar First Health at a maximum total cost of $18m. This represents an EV/EBITDA of 9.5x, potentially falling to 4.0x when targeted cost savings have been achieved. We will reassess our forecasts with the soon to be announced interims, but expect this acquisition to enhance FY 2016E EPS by c5% and FY 2017E by c10%."

Peppa is going down a storm in the USA: "100 Performances Added to PEPPA PIG's First-Ever U.S. Live Theatrical Tour" http://www.broadwayworld.com/bwwtv/article/100-Performances-Added-to-PEPPA-PIGs-First-Ever-US-Live-Theatrical-Tour-20150915 Extracts: "Peppa Pig is an absolute superstar among the preschool set and their families all across America and she will be making her biggest splash yet with the upcoming tour, now set to visit 65 additional cities in 2016," said Jonathan Shank, Red Light Management, a producer of Peppa Pig's Big|Brave Splash. "With many of the initial shows already sold out and many more performances added to accommodate the strong demand for tickets, Peppa Pig's theatrical tour is proving to be one hot ticket for families this fall!" "Peppa Pig's popularity continues to soar in the U.S. Families are flocking to major retailers nationwide, including Toys "R" Us, Walmart and Target, where hundreds of Peppa products have taken over shelves. Peppa is also a star on social media, connecting each day with her more than 2.5 million global followers on Facebook alone"

Canada Pension Plan buying the rest of Marwyn's stake at 269p per share: Http://www.investegate.co.uk/marwyn-value-inv-ltd--mvi-/rns/disposal-of-remaining-interest-in-eone/201509160745021962Z/ This removes any overhang at a stroke, and the buyers will certainly be extremely supportive long-term investors. The shares will now be quite tightly held. Hopefully we'll now see a return to 350p-370p. The market certainly likes the news.

FSJ have now been dropped out of the FTSE250 following last night's FTSE rejig after the poor results: Http://www.insidermedia.com/insider/national/146791-james-fisher-lonmin-and-premier-farnell-exit-ftse-250/ And Canaccord have dropped their price target to 1050p: Http://www.lulegacy.com/2015/08/29/james-fisher-sons-plc-price-target-cut-to-gbx-1050-by-analysts-at-canaccord-genuity-fsj/594447/ The latest broker forecasts from Singer and Canaccord are for around 66p EPS this year and 66p-69p EPS next year. I'd say a price of around 900p-1000p would be fair value at present given the above.

Canaccord have also increased their target price, to 920p... "0824 GMT House broker Canaccord Genuity lifts its target price on Accesso Technology Group to 920p from 720p despite a wider 1H pretax loss. The results reflect heavy investment to support an agreement with UK-listed theme park group Merlin Entertainments, says Canaccord. Notes that 2H has started well, boosted by better weather in the US. Also sees growth potential from geographical expansion. Keeps its buy rating on the stock. Shares drop 4.1% to 828p."

Decent trading statement - management here are doing the right things. The cash pile is actually increasing - up to around £9.5m, compared to the £7m m/cap. And underlying EBITDA is in line with expectations.

Nice to see blue here with the markets so depressed. Looking forward to seeing SOM present tomorrow (though my sore throat/cold may still prevent me attending!). Hopefully whilst they're here SOM are doing the rounds of a load of institutional investors and making the most of their visit.

Excellent Numis comments this morning... - the results were AHEAD of their expectations despite the advance Merlin costs - they've INCREASED their target price to 985p, whilst moving to Add - one major new customer is named - the One World Observatory, a significant attraction at One World Trade Centre in New York - Numis "understand from management that inbound customer interest has increased materially" after the Merlin announcement - Merlin noted in its interim results presentation that the accesso relationship "could be broadened to include queueing (currently c.3 venues out of a possible 15-20)" - "accesso is clearly the premier player in this space", and they see further upside to forecasts from Merlin etc

Results are pretty good for the much seasonally weaker H1, with revenues and adjusted profit well up yoy - despite much increased investment in the business to begin supporting the new Merlin contract etc. The strong start to H2 bodes well for the year, alongside the comments about reiterated expectations. Very encouraging to see that the queueless theme park trials are going well. Some short-term profit-taking today to be expected, particularly after the stellar share price rise. The big buying has been institutional investment for the long-term, and that's unlikely to dry up for a while yet.